|
|
| Line 1: |
Line 1: |
| {{SI}}
| | #REDIRECT [[Dipeptidyl peptidase-4 inhibitor]] |
| | |
| | |
| [[Image:Incretins_and_DPP_4_inhibitors.svg|thumb|300px|left|GLP-1 and DPP-4 inhibitors]]
| |
| | |
| '''[[Enzyme inhibitors|Inhibitors]] of [[Dipeptidyl peptidase 4]] ''', also '''[[dipeptidyl peptidase-4|DPP-4]] inhibitors''', are a new class of [[oral hypoglycemic]]s which block [[dipeptidyl peptidase-4|DPP-4]].
| |
| | |
| Their mechanism of action is thought to result from increased [[Incretin]] levels (GLP-1 and GIP),<ref> McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005 Jun 15;128(2):159-65. PMID:15780435 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15780435&query_hl=1&itool=pubmed_docsum].</ref><ref>Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord. 2003 Apr 10;3(1):3. PMID 12697069. [http://www.biomedcentral.com/1472-6823/3/3 Full Free Text].</ref><ref>Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
| |
| Diabetes. 1995 Jun;44(6):626-30. PMID 7789625.</ref> which, inhibit [[glucagon]] release
| |
| (which increases the [[blood glucose]]) but more importantly increase [[insulin]] secretion and decrease gastric emptying.
| |
| | |
| Drugs belonging to this class are [[vildagliptin]]<ref>{{UTGlucagon|laf237}} - Vildagliptin</ref>, [[sitagliptin]]<ref>{{UTGlucagon|mk-0431}} - Sitagliptin</ref> and [[saxagliptin]].
| |
| | |
| Although extensive long-term, pre-clinical studies of the major DPP-4 inhibitors has failed to show any evidence of potential to cause tumors in laboratory animals, there was one in-vitro (i.e., test tube) study that has raised some questions. <ref> [http://content.nejm.org/cgi/medline/pmid;16908079 Masur K et al. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells, Regul Pept. ,137 (3) p. 147-55 (2006)] PMID 16908079.</ref>
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| ==External links==
| |
| *[http://www.forbes.com/2004/01/26/cx_mh_rl_diabetestearsheet_5.html The race to get DPP-4 inhibitors to market] - Forbes.com
| |
| | |
| {{Oral_hypoglycemics}}
| |
| [[Category:Endocrinology]]
| |
| [[Category:Dipeptidyl peptidase-4 inhibitors| ]]
| |
| | |
| [[de:Inhibitoren der Dipeptidylpeptidase IV]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |